oral semaglutide vs tirzepatide Comparative safety and side effects of and tirzepatide: Implications for clinical decision-making in obesity management Semaglutide vs Tirzepatide, which is

Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, et al

Moreover, many patients maintain significant weight loss and sustain lower HbA1c levels with continued treatment, helping reduce long-term complications associated with diabetes

Although no significant adverse effects were observed in our study, including hemolysis, histopathological changes, and Mn ion accumulation, the potential risk of LAbs inducing tumorigenicity or undesired immunological responses following repeated administration should be systematically investigated

Saxenda was approved by the FDA in December 2014 for weight management for adults who are overweight or obese with a weight-related condition

Semaglutide is approved as a once-weekly subcutaneous injection , and the exact clock time (morning, afternoon, or evening) does not affect long-term exposure